BTLA

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
BTLA
Protein BTLA PDB 2aw2.png
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesBTLA, BTLA1, CD272, B and T lymphocyte associated
External IDsMGI: 2658978 HomoloGene: 52233 GeneCards: BTLA
Gene location (Human)
Chromosome 3 (human)
Chr.Chromosome 3 (human)[1]
Chromosome 3 (human)
Genomic location for BTLA
Genomic location for BTLA
Band3q13.2Start112,463,968 bp[1]
End112,499,561 bp[1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001085357
NM_181780

NM_001037719
NM_177584

RefSeq (protein)

NP_001078826
NP_861445

NP_001032808
NP_808252

Location (UCSC)Chr 3: 112.46 – 112.5 MbChr 16: 45.22 – 45.26 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

B- and T-lymphocyte attenuator is a protein that in humans is encoded by the BTLA gene.[5][6] BTLA has also been designated as CD272 (cluster of differentiation 272).

Function[edit]

BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4.[6] However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a ligand for tumour necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses.

Clinical significance[edit]

BTLA activation inhibits the function of human CD8+ cancer-specific T cells.[7]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000186265 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000052013 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (July 2003). "BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1". Nature Immunology. 4 (7): 670–9. doi:10.1038/ni944. PMID 12796776. 
  6. ^ a b "Entrez Gene: BTLA B and T lymphocyte associated". 
  7. ^ Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE (January 2010). "BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination". The Journal of Clinical Investigation. 120 (1): 157–67. doi:10.1172/JCI40070. PMC 2799219Freely accessible. PMID 20038811. Lay summaryGenetic Engineering & Biotechnology News. 

Further reading[edit]

  • Pao LI, Bedzyk WD, Persin C, Cambier JC (February 1997). "Molecular targets of CD45 in B cell antigen receptor signal transduction". Journal of Immunology. 158 (3): 1116–24. PMID 9013950. 
  • Pao LI, Cambier JC (March 1997). "Syk, but not Lyn, recruitment to B cell antigen receptor and activation following stimulation of CD45- B cells". Journal of Immunology. 158 (6): 2663–9. PMID 9058799. 
  • Vilen BJ, Famiglietti SJ, Carbone AM, Kay BK, Cambier JC (July 1997). "B cell antigen receptor desensitization: disruption of receptor coupling to tyrosine kinase activation". Journal of Immunology. 159 (1): 231–43. PMID 9200459. 
  • Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM (December 2003). "Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2". Biochemical and Biophysical Research Communications. 312 (4): 1236–43. doi:10.1016/j.bbrc.2003.11.070. PMID 14652006. 
  • Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, Murphy KM (January 2005). "B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator". Nature Immunology. 6 (1): 90–8. doi:10.1038/ni1144. PMID 15568026. 
  • Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, Eaton DL (January 2005). "A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator". Proceedings of the National Academy of Sciences of the United States of America. 102 (4): 1116–21. doi:10.1073/pnas.0409071102. PMC 544343Freely accessible. PMID 15647361. 
  • Cheung TC, Humphreys IR, Potter KG, Norris PS, Shumway HM, Tran BR, Patterson G, Jean-Jacques R, Yoon M, Spear PG, Murphy KM, Lurain NS, Benedict CA, Ware CF (September 2005). "Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway". Proceedings of the National Academy of Sciences of the United States of America. 102 (37): 13218–23. doi:10.1073/pnas.0506172102. PMC 1201609Freely accessible. PMID 16131544. 
  • Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG (November 2005). "Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex". The Journal of Biological Chemistry. 280 (47): 39553–61. doi:10.1074/jbc.M507629200. PMID 16169851. 
  • Otsuki N, Kamimura Y, Hashiguchi M, Azuma M (June 2006). "Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells". Biochemical and Biophysical Research Communications. 344 (4): 1121–7. doi:10.1016/j.bbrc.2006.03.242. PMID 16643847. 
  • Wang XF, Chen YJ, Wang Q, Ge Y, Dai Q, Yang KF, Zhou YH, Hu YM, Mao YX, Zhang XG (February 2007). "Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells". Tissue Antigens. 69 (2): 145–53. doi:10.1111/j.1399-0039.2006.00710.x. PMID 17257317. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.